Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

collaborations

- PMLiVE

Permission to pause: making treatment breaks part of the cancer care conversation

Exploring how empathetic, patient-centred communication can make planned treatment breaks easier to discuss as part of cancer care.

Cuttsy + Cuttsy

- PMLiVE

Johnson & Johnson announces change in senior leadership role

Tom Cavanaugh has been appointed as Executive Vice President, Worldwide Chairman Innovative Medicine

- PMLiVE

Johnson & Johnson commits $5.5bn to end remaining talc litigation

The resolution comes after plaintiffs were unable to prove that J&J’s talc products caused their ovarian cancer

- PMLiVE

Key takeaways from ASCO® 2026

Following ASCO® 2026, Inizio's experts have shared their perspectives across three thought leadership articles, each exploring a different aspect of what this year's congress revealed for pharmaceutical organisations. Together, they...

Inizio

- PMLiVE

Real Chemistry Launches Real Chemistry ANATOMI, an AI Ecosystem Purpose-Built for Healthcare Commercialization

The unique combination of technology marks 25 years of industry innovation and expertise, and signals company’s next phase of business growth and client value

Real Chemistry

- PMLiVE

Webcast | Smarter science, sharper strategy: Expert perspectives from ASCO® 2026

Key insights from ASCO® 2026, including oncology trends, scientific highlights, and strategies for smarter congress engagement.

Inizio

- PMLiVE

J&J’s Erleada prostate cancer study shows significant reduction in risk of metastasis

Erleada plus hormone therapy significantly improved key short- and long-term clinical outcomes

- PMLiVE

Pfizer and Innovent Biologics agree on deal worth up to $10.5bn

The companies plan to research and develop 12 new cancer treatments

- PMLiVE

The silent drop-off: How disengagement shows up in everyday behaviour

In healthcare, disengagement rarely announces itself. It doesn’t always appear as refusal or a clear decision to stop treatment. More often, it shows up quietly, in what is delayed, avoided...

Mednet

- PMLiVE

J&J’s Icotyde approved by US FDA for plaque psoriasis

Plaque psoriasis affects over 125 million people worldwide

- PMLiVE

One-carbon Therapeutics collaborates with Tempus in cancer treatment

The treatment is currently being evaluated in a phase 1/2 multicentre clinical study

- PMLiVE

Gilead to acquire Tubulis for up to $5bn

The acquisition builds on Gilead’s oncology pipeline, focused on addressing areas of high unmet need

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links